Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;88(4):208-13.
doi: 10.1159/000369257. Epub 2014 Dec 6.

A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients

Aminah Jatoi  1 , Carmen Radecki Breitkopf, Nathan R Foster, Matthew S Block, Megan Grudem, Andrea Wahner Hendrickson, Rachel E Carlson, Brigitte Barrette, Nina Karlin, Alan P Fields
Affiliations

A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients

Aminah Jatoi et al. Oncology. 2015.

Abstract

Purpose: This trial was undertaken (1) to determine the feasibility of enrolling asymptomatic ovarian cancer patients with CA-125 elevation in a trial with the protein kinase C iota (PKCι) inhibitor auranofin and (2) to understand patients' perceptions of CA-125 monitoring.

Methods: Asymptomatic ovarian cancer patients with CA-125 elevation received 3 mg auranofin orally twice per day and were evaluated. The patients participated in interviews about CA-125 monitoring.

Results: Ten patients were enrolled in slightly over 6 months, exceeding our anticipated accrual rate. Four manifested stable CA-125 levels for 1 month or longer. The median progression-free survival was 2.8 months (95% CI: 1.3-3.8); auranofin was well tolerated. One patient had baseline and monthly CA-125 levels of 5,570, 6,085, 3,511, and 2,230 U/ml, respectively, stopped auranofin because of radiographic progression at 3 months, and manifested an increase in CA-125 to 7,168 U/ml approximately 3 months later. Patient interviews revealed (1) the important role of CA-125 in cancer monitoring, (2) ardent advocacy of CA-125 testing, and (3) an evolution toward CA-125 assuming a life of its own.

Conclusions: This study showed the feasibility of enrolling asymptomatic ovarian cancer patients with CA-125 elevation in a trial with auranofin. One patient had a decline in CA-125, suggesting that PKCι inhibition merits further study in ovarian cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The percent change in Ca-125 levels from baseline appears for all 9 evaluable patients. One patient manifested a notable and sustained drop in Ca-125 of greater than 50%. Cycle length was one month.
Figure 2
Figure 2
The median progression-free survival for the cohort was 2.8 months (95% confidence interval: 1.3, 3.8 months).
See this image and copyright information in PMC

References

    1. Parker PJ, Justilien V, Riou P, Minch M, Fields AP. Atypical protein kinase C ι as a human oncogene and therapeutic target. Biochem Pharmacol. 2014;88:1–11. - PMC - PubMed
    1. Zhang L, Huang J, Yang N, et al. Integrative genomic analysis of protein kinase C family identified PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res. 2006;66:4627–35. - PubMed
    1. Wang Y, Jill KS, Fields AP. PKCι maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis. Mol Cancer Res. 2013l;11:1624–35. - PMC - PubMed
    1. Mansfield AS, Fields AP, Jatoi A, Qi Y, Adjei AA, Erlichman C, Molina JR. Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs. 2013;24:1079–83. - PMC - PubMed
    1. Syrios J, Banerjee S Kaye SB. Advanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets – where are we now? Anticancer Res. 2014;34:2069–77. - PubMed

Publication types

MeSH terms